PURPOSE: Asthma is one of the most common obstructive pulmonary diseases worldwide. Epigenetic alterations, including DNA methylation and histone modifications, have been reported to contribute to asthma pathogenesis. Since the inflammation mediator and remodeling trigger, IL-13, is known to play a central role in the pathophysiology of asthma, this study was aimed to identify novel IL-13-regulated epigenetic modifiers in asthma that may contribute to subepithelial fibrosis. METHODS: Publicly available transcriptomic datasets from Gene Expression Omnibus (GEO) were used to identify differentially expressed genes on an epigenetic level upon IL-13 exposure in lung fibroblasts. Bronchial fibroblasts isolated from healthy and asthmatic individuals were assessed for the gene and protein expression levels of the identified gene at baseline and upon IL-13 treatment using qRT-PCR and western blotting, respectively. Its subcellular localization and tissue distribution were examined in bronchial fibroblasts as well as bronchial biopsies by immunofluorescence and immunohistochemical analysis, respectively. RESULTS: Bioinformatic analysis revealed the differential expression of the histone demethylase JMJD2B/KDM4B, a well-known epigenetic modulator that leads to the demethylation of different lysine residues on histones, in IL-13-treated lung fibroblasts. The baseline expression levels of JMJD2B were higher in asthmatic fibroblasts and in bronchial biopsies in comparison to healthy ones. There was also an increase in JMJD2B activity as evidenced by the demethylation of its downstream target, H3K36me3. Furthermore, IL-13 stimulation induced JMJD2B expression and further demethylation of H3K36me3 in asthmatic fibroblasts. This was accompanied by increased translocation of JMJD2B into the nucleus. CONCLUSION: This study highlights the novel pathological involvement of the histone demethylase JMJD2B/KDM4B in asthmatic airway fibroblasts that are regulated by IL-13. Clinical implications. Given that there is no single therapeutic medicine to effectively treat the various subtypes of asthma, this study provides promising insights into JMJD2B as a new therapeutic target that could potentially improve the treatment and management of asthma.
PURPOSE: Asthma is one of the most common obstructive pulmonary diseases worldwide. Epigenetic alterations, including DNA methylation and histone modifications, have been reported to contribute to asthma pathogenesis. Since the inflammation mediator and remodeling trigger, IL-13, is known to play a central role in the pathophysiology of asthma, this study was aimed to identify novel IL-13-regulated epigenetic modifiers in asthma that may contribute to subepithelial fibrosis. METHODS: Publicly available transcriptomic datasets from Gene Expression Omnibus (GEO) were used to identify differentially expressed genes on an epigenetic level upon IL-13 exposure in lung fibroblasts. Bronchial fibroblasts isolated from healthy and asthmatic individuals were assessed for the gene and protein expression levels of the identified gene at baseline and upon IL-13 treatment using qRT-PCR and western blotting, respectively. Its subcellular localization and tissue distribution were examined in bronchial fibroblasts as well as bronchial biopsies by immunofluorescence and immunohistochemical analysis, respectively. RESULTS: Bioinformatic analysis revealed the differential expression of the histone demethylase JMJD2B/KDM4B, a well-known epigenetic modulator that leads to the demethylation of different lysine residues on histones, in IL-13-treated lung fibroblasts. The baseline expression levels of JMJD2B were higher in asthmatic fibroblasts and in bronchial biopsies in comparison to healthy ones. There was also an increase in JMJD2B activity as evidenced by the demethylation of its downstream target, H3K36me3. Furthermore, IL-13 stimulation induced JMJD2B expression and further demethylation of H3K36me3 in asthmatic fibroblasts. This was accompanied by increased translocation of JMJD2B into the nucleus. CONCLUSION: This study highlights the novel pathological involvement of the histone demethylase JMJD2B/KDM4B in asthmatic airway fibroblasts that are regulated by IL-13. Clinical implications. Given that there is no single therapeutic medicine to effectively treat the various subtypes of asthma, this study provides promising insights into JMJD2B as a new therapeutic target that could potentially improve the treatment and management of asthma.
Authors: Elmar W Tobi; Bastiaan T Heijmans; Dennis Kremer; Hein Putter; Henriette A Delemarre-van de Waal; Martijn J J Finken; Jan M Wit; P Eline Slagboom Journal: Epigenetics Date: 2011-02-01 Impact factor: 4.528
Authors: Reynold A Panettieri; Ulf Sjöbring; AnnaMaria Péterffy; Peter Wessman; Karin Bowen; Edward Piper; Gene Colice; Christopher E Brightling Journal: Lancet Respir Med Date: 2018-05-20 Impact factor: 30.700
Authors: Aik T Ooi; Sonal Ram; Alan Kuo; Jennifer L Gilbert; Weihong Yan; Matteo Pellegrini; Derek W Nickerson; Talal A Chatila; Brigitte N Gomperts Journal: Am J Transl Res Date: 2012-04-10 Impact factor: 4.060
Authors: Erika H De Boever; Claire Ashman; Anthony P Cahn; Nicholas W Locantore; Phil Overend; Isabelle J Pouliquen; Adrian P Serone; Tracey J Wright; Mair M Jenkins; Inderpal S Panesar; Sivayogan S Thiagarajah; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793
Authors: Rafael Firszt; Dave Francisco; Tony D Church; Joseph M Thomas; Jennifer L Ingram; Monica Kraft Journal: Eur Respir J Date: 2013-05-16 Impact factor: 16.671
Authors: Simone F Glaser; Andreas W Heumüller; Lukas Tombor; Patrick Hofmann; Marion Muhly-Reinholz; Ariane Fischer; Stefan Günther; Karoline E Kokot; David Hassel; Sandeep Kumar; Hanjoong Jo; Reinier A Boon; Wesley Abplanalp; David John; Jes-Niels Boeckel; Stefanie Dimmeler Journal: Proc Natl Acad Sci U S A Date: 2020-02-07 Impact factor: 11.205